Related Experiment Video
Updated: Sep 13, 2025
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Goal Achievement in 3017 Patients at Very High Cardiovascular Risk Based on Different LDL Cholesterol Calculations
István Reiber1, Laszlo Mark2, Hajnalka Lőrincz3
1Department of Medicine, St George University Teaching Hospital of Fejer County, 8000 Szekesfehervar, Hungary.
Insights
High-intensity rosuvastatin and rosuvastatin/ezetimibe combination therapy improved lipid goal achievement in very high-risk patients. Combination therapy showed higher achievement rates, but calculation methods for non-HDL-C can be inaccurate.
Area of Science:
- Cardiology
- Pharmacology
- Lipid Metabolism
Background:
- Very high-risk patients often require intensive lipid-lowering therapy to achieve treatment goals.
- Rosuvastatin and ezetimibe are key agents in managing dyslipidemia, particularly in high-risk populations.
- Accurate assessment of lipid goal achievement is crucial for effective cardiovascular risk management.
Purpose of the Study:
- To evaluate lipid goal achievement rates in very high-risk patients treated with high-intensity rosuvastatin monotherapy versus a rosuvastatin/ezetimibe combination.
- To compare the efficacy of two different lipid-lowering strategies over a six-month period.
- To assess the impact of different calculation methods on non-high-density lipoprotein cholesterol (non-HDL-C) goal attainment.
Main Methods:
- Prospective, observational study involving 3017 very high-risk patients across 210 general and specialist practices.
- Patients received either high-intensity rosuvastatin monotherapy or a fixed-dose rosuvastatin/ezetimibe combination for six months.
- Lipid goal achievement was assessed using LDL-C and non-HDL-C targets, with LDL-C calculated via multiple methods (Martin-Hopkins, Sampson, Friedewald).
Main Results:
- The rosuvastatin/ezetimibe combination therapy achieved LDL-C goals more effectively (52% for 1.8 mmol/L, 22% for 1.4 mmol/L) compared to rosuvastatin monotherapy (37% for 1.8 mmol/L, 11% for 1.4 mmol/L).
- LDL-C reduction of at least 50% was observed in 42% of patients on combination therapy versus 32% on monotherapy.
- Non-HDL-C goal achievement rates were higher than LDL-C rates, but inaccuracies were noted when using standard adjustments for non-HDL-C calculation, especially in patients with lower triglyceride levels.
Conclusions:
- Fixed-dose combination therapy with high-intensity rosuvastatin and ezetimibe significantly improves lipid goal achievement in very high-risk patients.
- Standard methods for calculating non-HDL-C, particularly the addition of 0.8 mmol/L, can lead to inaccuracies, especially in patients with low triglyceride levels.
- Optimizing lipid management requires careful consideration of therapy choice and accurate lipid measurement methodologies.
Abstract:
Objectives: The goal of this study was to investigate lipid goal achievement rates in very high-risk patients over six months using high-intensity rosuvastatin or rosuvastatin/ezetimibe combination lipid-lowering therapy. Methods: This prospective, observational study was conducted on the patients of 150 general and 60 specialist practices. Our analysis included 3017 patients (47% women) who completed six months of therapy. Of these, 55.5% had pre-existing cardiovascular disease, 35.6% had cerebrovascular disease, and 20.4% had peripheral vascular disease. Results: At six months, in patients receiving rosuvastatin monotherapy (20.5%), the 1.8 LDL-C achievement rate was 37%; in those taking the fix rosuvastatin/ezetimibe combination (63.7%), it was 52%, and the 1.4 level attainment proved to be 11% and 22%, respectively. The rates of LDL-C reduction of at least 50% were 32% and 42%, respectively. Overall, non-HDL-C goal achievement rates were higher than when LDL-C was calculated using the Martin-Hopkins or Sampson methods but similar to those calculated with the Friedewald formula. When patients were stratified by triglyceride quartiles, non-HDL-C goal achievement rates were significantly higher (p < 0.001) in cases with triglyceride levels below 1.2 mmol/L. Conversely, Friedewald-calculated LDL-C (F-LDL-C) goal achievement rates were significantly higher (p < 0.001) in patients with triglyceride levels above 1.7 mmol/L. Conclusions: Our findings suggest that the consistent use of fixed high-intensity statin and ezetimibe combinations can improve lipid goal achievement. However, comparing the achievement of LDL-C goals (calculated by three methods) and non-HDL-C goals also confirmed that the common practice of automatically adding 0.8 mmol/L to the calculated LDL-C value to determine non-HDL-C leads to inaccuracies, particularly in the lower triglyceride ranges.
Related Concept Videos
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:18Lipids: Dietary Sources and Requirements
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents